Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer September 6-9, 2015

By: via Benzinga
Clovis Oncology (NASDAQ: CLVS) today announced that rociletinib, the company's oral targeted covalent (irreversible) mutant-selective ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.